Beschrijving
In this episode, James & Sapna tease the size of ASCO and ESMO and number of simultaneous publications.
They review the most impactful melanoma and Merkel cell carcinoma presentations from ASCO 2026, focusing on practice-changing trials and innovative strategies that could shape future treatment landscapes.
Studies discussed include:
• OptimUM-02 phase 2/3 trial for metastatic uveal melanoma
• ADAM phase 3 trial for MCC
• 5yr update of the phase 2 Keynote 942 trial (adjuvant melanoma)
• Pilot neoadjuvant studies (NeoReNi, NeoINR)
• Time of day of infusion and immunotherapy efficacy
Website: podcasters.spotify.com

